{
    "relation": [
        [
            "Arms",
            "Experimental: Panel A - MK6186 40 mg MK6186 40 mg",
            "Placebo Comparator: Panel A - Placebo placebo",
            "Experimental: Panel B - MK6186 150 mg MK6186 150 mg",
            "Placebo Comparator: Panel B - Placebo placebo",
            "Experimental: Panel C - MK6186 <=150 mg MK6186 <=150 mg",
            "Placebo Comparator: Panel C - Placebo placebo",
            "Experimental: Panel D - MK6186 <=150 mg MK6186 <=150 mg",
            "Placebo Comparator: Panel D - Placebo placebo"
        ],
        [
            "Assigned Interventions",
            "Drug: MK6186 Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose <= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose <= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)",
            "Drug: Comparator: Placebo Placebo tablets taken orally for seven day",
            "Drug: MK6186 Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose <= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose <= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)",
            "Drug: Comparator: Placebo Placebo tablets taken orally for seven day",
            "Drug: MK6186 Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose <= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose <= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)",
            "Drug: Comparator: Placebo Placebo tablets taken orally for seven day",
            "Drug: MK6186 Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose <= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose <= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)",
            "Drug: Comparator: Placebo Placebo tablets taken orally for seven day"
        ]
    ],
    "pageTitle": "MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2) - Full Text View - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/NCT01152255?term=%22+June+16%2C++2010%22%3A%22+July+16%2C++2010%22%5BFIRST-RECEIVED-DATE%5DAND+HIV%5BCONDITION%5D&rank=18",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438043058631.99/warc/CC-MAIN-20150728002418-00317-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 880567338,
    "recordOffset": 880559136,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "June 2011 (Final data collection date for primary outcome measure) Primary Completion Date: June 2011 Study Completion Date: October 2010 Study Start Date: 18 Enrollment: C(24 hour) of MK6186 [\u00a0Time\u00a0Frame:\u00a0Day 7\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Secondary Outcome Measures: Safety and tolerability of MK6186 measured by number of clinical and laboratory adverse experiences [\u00a0Time\u00a0Frame:\u00a0through Day 21\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0] Change from baseline in plasma HIV-1 RNA [\u00a0Time\u00a0Frame:\u00a0Baseline and Day 7\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Primary Outcome Measures: Further study details as provided by Merck Sharp & Dohme Corp.: U.S. FDA Resources HIV/AIDS MedlinePlus related topics: Resource links provided by NLM:",
    "textAfterTable": "\u00a0 Eligibility Ages Eligible for Study: \u00a0 18 Years to 55 Years Genders Eligible for Study: \u00a0 Both Accepts Healthy Volunteers: \u00a0 No Criteria Inclusion Criteria: Other than HIV infection, patient's baseline health is judged to be stable Patient is documented HIV-1 positive Patient has not received an investigational agent or licensed ART with in the past 30 days Exclusion Criteria: Patient has a history of stroke, chronic seizures, or major neurological disease Patient has a history of cancer Patient has used any immune therapy agents or immunosuppressive therapy within the past month Patient requires or anticipates the use of any prescription or non-prescription drugs during the study Patient has a current diagnosis of acute hepatitis, has a history of Hepatitis C or has positive Hepatitis B surface antigen Patient consumes excessive amounts of alcohol (greater than 3 servings per day) or caffeine (greater than 6 servings per day)",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}